In CLL patients treated with pentostatin, cyclophosphamide and rituximab showing high expression of Mcl-1, both minimal residual disease-negative status and progression-free survival were found to be significantly reduced (Awan et al, 2009). This evidence concerns the gene MCL1 and B-cell chronic lymphocytic leukemia.